ARBUTUS BIOPHARMA CORPORATION

Analyst Reco. Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.75 ^USD	+0.36%		-1.08%	+10.00%

Apr. 05	Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	MT
Apr. 04	Moderna Suffers Setback in Lawsuit by Arbutus	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Trims Price Target on Arbutus Biopharma to $5 From $6, Keeps Buy Rating	Mar. 01	MT
JMP Securities Adjusts Arbutus Biopharma Price Target to $4 From $6, Maintains Market Outperform Rating	23-09-12	MT
HC Wainwright Adjusts Price Target on Arbutus Biopharma to $6 From $7.50, Maintains Buy Rating	22-11-10	MT
JMP Securities Adjusts Arbutus Biopharma Price Target to $9 From $10, Maintains Market Outperform Rating	22-06-28	MT
HC Wainwright Adjusts Arbutus Biopharma's Price Target to $8.50 From $8, Maintains Buy Rating	22-03-14	MT
Chardan Research Adjusts Arbutus Biopharma's Price Target to $6 From $5.50; Buy Rating Kept	22-03-04	MT
Jefferies Upgrades Arbutus Biopharma to Buy From Hold, Adjusts Price Target to $5 From $4	22-02-02	MT
HC Wainwright Adjusts Arbutus Biopharma PT to $8 From $10, Maintains Buy Rating	21-11-08	MT
JMP Securities Adjusts Price Target on Arbutus Biopharma to $9 From $7, Maintains Market Outperform Rating	21-11-08	MT
ARBUTUS BIOPHARMA : Wedbush Adjusts Price Target on Arbutus Biopharma to $6 From $7, Keeps Outperform Rating	21-03-08	MT
ARBUTUS BIOPHARMA : Jefferies Starts Arbutus Biopharma at Hold With $5 Price Target	21-02-25	MT
ARBUTUS BIOPHARMA : HC Wainwright Starts Arbutus Biopharma at Buy With $10 Price Target	20-12-17	MT
ARBUTUS BIOPHARMA : Wedbush Adjusts Arbutus Biopharma's Price Target to $7 From $5 Following Updated AB-729 Data, Keeps at Outperform	20-11-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer